𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Out-of-pocket expenses and their burden in patients with rheumatoid arthritis

✍ Scribed by Wolfe, Frederick ;Michaud, Kaleb


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
119 KB
Volume
61
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Compliance with biologic therapies for r
✍ Curkendall, S. ;Patel, V. ;Gleeson, M. ;Campbell, R. S. ;Zagari, M. ;Dubois, R. πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 1 views

## Abstract ## Objective To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA). ## Methods An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was s

Burden of caregiving: Evidence of object
✍ Brouwer, Werner B. F. ;van Exel, N. Job A. ;van de Berg, Bernard ;Dinant, Huib J πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 85 KB

## Abstract ## Objective To improve understanding of the nature and magnitude of the burden of informal care and also to indicate important areas for improving the current ways in which informal care is investigated. ## Methods Information on objective burden (such as care tasks performed and ti

Risk of malignant lymphomas in patients
✍ Karin EkstrΓΆm; Henrik Hjalgrim; Lena Brandt; Eva Baecklund; Lars Klareskog; Ande πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) are at increased risk for malignant lymphomas. Both conditions display a familial aggregation, and there are reports of RA and malignant lymphomas occurring in the same families. This study was undertaken to determine the risk of mal

Pharmacokinetics of oral methotrexate in
✍ Judith M. Dalrymple; Lisa K. Stamp; John L. O'Donnell; Peter T. Chapman; Mei Zha πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 282 KB πŸ‘ 2 views

## Abstract ## Objective There is evidence supporting a therapeutic range for methotrexate polyglutamate (MTXGlu) concentrations in the treatment of rheumatoid arthritis (RA). Knowledge of the pharmacokinetics of MTXGlu~1–5~ is required for optimal timing of blood sampling. The aim of this study w